Prevention and treatment of DNA vaccine encoding cockroach allergen Bla g 1 in a mouse model of allergic airway inflammation

Department of Medicine, University of Tennessee Health Science Center, Memphis, USA.
Allergy (Impact Factor: 6.03). 09/2011; 67(2):166-74. DOI: 10.1111/j.1398-9995.2011.02727.x
Source: PubMed


One-fourth of the US population is sensitized to the German cockroach. Primary German cockroach allergen Bla g 1 is detected in 63% of homes and 52% of childcare facilities in the United States. No effective treatment or vaccination strategies are yet available.
We evaluated the prophylactic and therapeutic efficacy of a plasmid DNA-mediated vaccination using the Bla g 1 gene in a mouse model of allergic inflammatory airway disease.
A plasmid DNA vector coding for the Bla g 1 allergen controlled by cytomegalovirus promoter was constructed. To estimate the protective efficacy, BALB/c mice were given three injections of plasmid DNA-Bla g 1 prior to sensitization with two priming doses of recombinant Bla g 1 (rBla g 1) antigens, followed by nebulized rBla g 1 challenge. In the therapeutic approach, sensitization was followed by administering Bla g 1 DNA vaccine.
Bla g 1 vaccination significantly reduced allergen-induced airway inflammation, even after mice were presensitized and a Th2-dominant response was established. The Bla g 1 vaccination significantly reduced total inflammatory cell infiltrate, eosinophilia, secretion of Th2 cytokines IL-4 and IL-5 in bronchoalveolar lavage fluid, allergen-induced inflammatory infiltrates in the lungs, and Bla g 1-specific IgE in serum upon challenge with rBla g 1. Importantly, Bla g 1 DNA vaccination was able to induce IL-10-secreting regulatory T cells that could suppress the allergen-specific Th2 cells.
DNA vaccination showed protective and therapeutic efficacy against a clinically relevant allergen Bla g 1.

Download full-text


Available from: Taijune Yoo, Sep 03, 2014
  • Source
    • "DNA vaccination is a recently developed approach in which genes that encode target antigens are delivered and expressed in vivo within host cells. This technique has been proven to be very effective and promising in mouse models of infectious diseases, cancers and other autoimmune disorders including multiple sclerosis, experimental autoimmune encephalomyelitis and allergic responses [16] [21] [22] [23] [24] [25] [26]. One of the major disadvantages of DNA vaccination which limits its clinical application is the restricted ability to induce strong immunity in the host [27]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Monocytes utilise a variety of chemokines to traffic to atherosclerotic plaques. CX3C chemokine ligand 1 (CX3CL1 & Fractalkine) and its receptor CX3CR1 and monocyte chemoattractant protein 1 (CCL2) have been identified as chemokines/receptors that have an important role in the migration and recruitment of monocytes during the pathogenesis of several inflammatory diseases including atherosclerosis. DNA vectors containing single chain variable region fragment (scFv) for DC-targeted receptor DEC205 were cloned with mouse CX3CR1 and CCL2 genes respectively, and vaccinated into C57/BL6 mice weekly for 3 weeks. Induced anti-CX3CR1 and anti-CCL2 in vaccinated mice was examined by ELISA and Western Blot analysis, while the cellular response was examined by ELISPOT. The inhibition of chemotaxis of J774 macrophages to Py-4-1 endothelial cells was examined by in vitro transwell migration assay using serum collected from vaccinated mice. All vaccinated mice generated anti-CX3CR1 and anti-CCL2 Ab and cellular response by 8 weeks after DNA vaccination. Macrophage migration towards TNF-α activated endothelial cells was significantly inhibited by serum containing both anti-CX3CR1 or anti-CCL2 Ab from vaccinated mice. These results demonstrate that DC-targeting of DNA vaccines to self-antigens generates functional immune responses which can inhibit specific key chemotactic targets. This suggests a potential therapeutic role for chemokine/receptor DNA vaccination in atherosclerosis, where chemotaxis has a pivotal role in the inflammatory process.
    Full-text · Article · Jan 2012 · International Journal of Clinical and Experimental Medicine
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this research was to evaluate the fumigant activity of essential oils obtained from aerial parts of three Lamiaceae plants [Mentha longifolia L. subsp. typhoides (Brig.) Harley, Dorystoechas hastata Boiss. & Heldr. ex Bentham (endemic), and Origanum minutiflorum O. Schwarz et. H. Davis (endemic)] which naturally grow in Antalya region on 10-15 days old (2nd or 3rd instar) nymphs of German cockroach (Blattella germanica L.) at different concentrations ranging from 25 to 500 µl/L. GC- MS analysis revealed the presence of 1,8-cineole (25.9%), borneol (18.98%) and camphor (16.93%) in D. hastata, car-vacrol (97.93%) in O. minutiflorum, as well as cis-piperitone epoxide (53.25%) and piperitenone oxide (31.46%) in M. longifolia subsp. typhoides. When all essential oils were compared on the basis of fumigant toxicity, D. hastata essential oil is a more statistically significant fumigant than the other two essential oils at 100, 200 and 300 µl/L levels. There is no significant difference found at these concentrations between M. longifolia and O. minutiflorum essential oils. Moreover, at application levels of 400 and 500 µl/L, the most toxic essential oil was also from D. hastata, followed by those of M. longifolia and O. minutiflorum, respectively.
    No preview · Article · Jun 2012 · Fresenius Environmental Bulletin
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Evidence suggests a causal relationship between obesity and asthma; however, the underlying mechanisms remain unknown. Substance P (SP), involved in neurogenic inflammation by acting through its receptor NK1-R, seems to participate in obese–asthma phenotype in mice. To evaluate the effect of a selective substance P receptor antagonist on a mouse model of diet-induced obesity and asthma. Diet-induced obese Balb/c mice were sensitized and challenged with ovalbumin (OVA) and treated with a selective NK1-R antagonist or placebo. Serum glucose, insulin, IL-6, resistin, and OVA-specific IgE levels were quantified. A score for peribronchial inflammation in lung histology was used. Cells were counted in bronchoalveolar lavage fluid. Adipocyte sizes were measured. Ovalbumin-obese mice treated with NK1-R antagonist had lower weight (P = 0.0002), reduced daily food intake (P = 0.0021), reduced daily energy intake (P = 0.0021), reduced surface adipocyte areas (P < 0.0001), lower serum glucose (P = 0.04), lower serum insulin (P = 0.03), lower serum IL-(P = 0.0022), lower serum resistin (P = 0.0043), lower serum OVA-specific IgE (P = 0.035), and lower peribronchial inflammation score (P < 0.0001) than nontreated OVA-obese mice. We observed an interaction between obesity, allergen sensitization, and treatment with NK1-R antagonist for metabolic and systemic biomarkers, and for allergen sensitization and bronchial inflammation, showing a synergy between these variables. In an experimental model of obesity and asthma in mice, NK1-R blockade improved metabolic and systemic biomarkers, as well as allergen sensitization and bronchial inflammation. These positive effects support a common pathway in the obese–asthma phenotype and highlight SP as a target with potential clinical interest in the obese–asthma epidemics.
    Full-text · Article · Nov 2012 · Allergy
Show more